Hims & Hers Health (HIMS) Stock Looks Like A Bargain On Sales But Mixed On Broader Checks

Hims & Hers Health stock has surged over the last three years, yet recent share price setbacks and a mixed valuation score leave investors weighing how much of the story is already reflected in the current price.

• The stock is up about 3.2x over the past three years. That puts extra focus on whether that strong run can be supported by future business performance.

• Plans to expand into experimental peptide therapies may support higher long term growth expectations. At the same time, regulatory and legal scrutiny around privacy, billing and payment disputes can weigh on how much investors are willing to pay for the stock.

• On Simply Wall St’s broader checks, Hims & Hers Health scores a 3 out of 6 on value, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Hims & Hers Health’s recent share price level fairly reflects these cross currents in growth potential, regulatory risk and current valuation checks.

Spot opportunities beyond Hims & Hers Health by comparing this story with a curated list of 44 high quality undervalued stocks that pair business quality with what could be more modest pricing.

Is Hims & Hers Health a Bargain on Sales?

The P/S ratio suits Hims & Hers Health because the business is currently oriented around revenue growth rather than consistent profits. The stock trades on a P/S of about 2.6x, compared with a Healthcare industry average of roughly 1.4x and a peer group average near 2.3x. That puts Hims & Hers Health at a premium to the wider sector and a smaller premium to closer peers, which reflects how the market is weighing its telehealth model and subscription driven revenue mix.

The tailored fair P/S ratio from Simply Wall St’s model is 5.1x, which is materially higher than the current 2.6x level. This indicates that the present price does not fully align with the multiple implied by the company’s growth profile, risk factors and margins. Despite the recent pressure around FTC and Visa disputes, the shares still screen at a discount to this fair P/S yardstick.

On the preferred P/S measure, Hims & Hers Health stock currently appears undervalued relative to the multiple suggested by its fundamentals.

See what the numbers say about this price — find out in our valuation breakdown.

The Hims & Hers Health Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives take the valuation puzzle around Hims & Hers Health and spell out which paths for growth, margins and earnings would need to play out for the stock to look meaningfully cheaper or more expensive than it does today, based on assumptions you can inspect. Each narrative sets out a fair value as a thesis about Hims & Hers Health’s business that you can watch over time. They are available on Simply Wall St’s Community page.

Community views on Hims & Hers Health are split between a full throttle growth story and a thesis that current expectations already look demanding.

Bull case: 83% undervalued

“Latest news of investments (Ohio facility expansion), acquisitions (YourBio, Livewell, GRAIL Inc. stake, Eucalyptus) and category expansion (Hims TRT, Hers Menopause, Labs) reflects high confidence in demand for new offerings…”

Read the full Bull Case to see why Hims & Hers Health could be undervalued

Bear case: 25% overvalued

“Regulatory and consumer pressures threaten user growth, pricing power, and margins, especially amid expanding generic competition and industry shifts toward price transparency…”

Read the full Bear Case to see why Hims & Hers Health could be overvalued

Do you think there’s more to the story for Hims & Hers Health? Head over to our Community to see what others are saying!

The Bottom Line

For Hims & Hers Health, the current valuation screens as undervalued on the preferred P/S measure, yet the broader checks remain mixed rather than emphatically cheap. The recent sharp share price move makes that gap more important, since expectations can quickly get ahead of what the underlying business can deliver. The crux now is whether growth and margins can develop in a way that keeps supporting the premium P/S while regulatory and legal risks do not erode that thesis. The key question for investors is whether the present discount to the tailored multiple represents an opportunity or fair compensation for those uncertainties.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HIMS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com